BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/24/2025 6:02:30 AM | Browse: 58 | Download: 0
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Letter to the Editor |
Article Title |
Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Fei-Yu Zhao, Xiao-Ming Zhang and Nian-Song Qian |
Funding Agency and Grant Number |
|
Corresponding Author |
Nian-Song Qian, Chief Physician, MD, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100853, China. qianniansong1@163.com |
Key Words |
Hepatocellular carcinoma; Bevacizumab; Lenvatinib; Sintilimab; Interventional treatment |
Core Tip |
Interventional therapy combined with immunotherapy and targeted therapy can significantly prolong the survival of intermediate and advanced hepatocellular carcinoma, but there are very few comparative studies studying the combination of different molecular targeted drugs, different immunotherapeutic drugs, and interventional therapy. Han et al studied the efficacy of lenvatinib or bevacizumab combined with sintilimab and interventional therapy, which can help clarify the efficacy of the combination of different drugs, providing a basis for clinicians to choose the correct treatment strategy for intermediate and advanced hepatocellular carcinoma. |
Citation |
Zhao FY, Zhang XM, Qian NS. Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy. World J Gastroenterol 2025; In press |
 |
Received |
|
2024-12-19 15:35 |
 |
Peer-Review Started |
|
2024-12-20 01:35 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-01-10 01:28 |
 |
Revised |
|
2025-01-13 10:06 |
 |
Second Decision |
|
2025-01-24 02:36 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-01-24 06:02 |
 |
Articles in Press |
|
2025-01-24 06:02 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345